Arcturus Therapeutics

60 articles about Arcturus Therapeutics

• Arcturus Therapeutics Receives Intent To Grant Notice From The European Patent Office For Their Unlocked Nucleomonomer Agent (UNA) Technology

  3/16/2016

• Arcturus Therapeutics Announces The Appointment Of Drew Weissman M.D., Ph.D. To The Scientific Advisory Board

  11/3/2015

• Arcturus Therapeutics Stands to Collect Up to $1.66 Billion from Rare Disease Pact with Ultragenyx

  10/30/2015

• Arcturus Therapeutics Announces Strategic Collaboration With Johnson & Johnson Innovation To Discover And Develop RNA Medicines For Defined Indications

  6/11/2015

• Arcturus Therapeutics To Present Messenger RNA Pipeline At The 33rd Annual J.P. Morgan Healthcare Conference And The 7th Annual Biotech Showcase

  1/7/2015

• Arcturus Therapeutics Announces The Appointment Of Michael R. Hodges, M.D. To The Scientific Advisory Board

  12/9/2014

• Arcturus Therapeutics To Present At The Genetic Rx Boston Biotech Conference

  12/5/2014

• Arcturus Therapeutics To Present At The 26th Annual Piper Jaffray Healthcare Conference

  12/1/2014

• Arcturus Therapeutics Presents Preclinical Messenger RNA Data In Non-Human Primates At The 2nd International mRNA Health Conference

  11/10/2014

• Arcturus Therapeutics To Present Gene Knockdown Data In Non-Human Primates, Showing Up To 94% Reduction In Gene Expression With A Single Low Dose

  10/13/2014

• Arcturus Therapeutics Appoints Robert Baltera And Stuart Collinson, Ph.D. To Its Board Of Directors

  5/6/2014

• Arcturus Therapeutics To Present At The 13th Annual Needham Healthcare Conference

  4/7/2014

• Arcturus Therapeutics To Present At The BioCentury Future Leaders In The Biotech Industry Conference

  3/27/2014

• Arcturus Therapeutics To Present At The Biotechnology Industry Organization (BIO)-Europe Spring Partnering Conference

  3/10/2014

• Arcturus Therapeutics To Present At The Keystone Symposia Conference On RNA Silencing

  1/30/2014

• Arcturus Therapeutics Announces An Rnai Therapeutic Targeting Transthyretin-Mediated Amyloidosis As Its Flagship Program

  1/13/2014

• Arcturus Therapeutics To Present At The Biotech Showcase 2014

  1/7/2014

• Arcturus Therapeutics Appoints Zachary A. Zimmerman, Ph.D., as Chief Business Officer

  10/28/2013

• Arcturus Therapeutics Raises $5 Million in Series A Funding to Maintain its Momentum in Nominating Lead Clinical Candidate in 2014

  10/21/2013

• Arcturus Therapeutics Acquires Cutting-Edge UNA Patent Estate From Marina Biotech, Inc.

  8/14/2013